Cosmos Health Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenues of $18.99 million for the quarter, marking a 28.8% increase from $14.75 million in the same period last year. For the first half of 2026, revenues reached $36.91 million, up 29.7% from $28.46 million in the prior year. Despite this growth, the company recorded a net loss of $6.09 million for the quarter, a substantial increase from a loss of $2.83 million in the same quarter of 2025. The six-month net loss also widened to $8.89 million from $3.65 million year-over-year.
The increase in revenue was primarily driven by higher sales from subsidiaries Decahedron Ltd, Cosmofarm S.A., and Cana S.A., with Decahedron nearly doubling its revenue compared to the previous year. However, the overall financial performance was impacted by non-cash items, including a $2.38 million loss from the change in fair value of convertible notes and a $404,145 loss on digital assets. The company also faced challenges with revenue reversals related to its distributor, Medihelm, which affected gross profit margins.
In terms of strategic developments, Cosmos Health has been actively expanding its operations through acquisitions and partnerships. The company completed the acquisition of Cana Laboratories in June 2023, enhancing its manufacturing capabilities, and has also entered into exclusive distribution agreements for its nutraceutical products in the UAE. The company reported that it has received significant purchase orders under this agreement, which are expected to contribute positively to cash inflows in the near term.
Operationally, Cosmos Health has seen an increase in its customer base, adding over 75 new pharmacies during the reporting period. The company’s employee headcount has remained stable, with ongoing efforts to optimize its workforce and enhance operational efficiencies. As of June 30, 2026, the company held total cash and restricted cash of $2.45 million, a decrease from $3.46 million at the end of 2025, reflecting net cash outflows primarily from operating activities.
Looking ahead, Cosmos Health's management has expressed concerns regarding its ability to continue as a going concern, citing substantial doubt due to ongoing losses and cash flow challenges. The company plans to pursue additional financing options, including potential equity offerings and strategic partnerships, to support its operations and growth initiatives. Management is focused on expanding its product portfolio and distribution channels while addressing liquidity constraints to ensure the sustainability of its business model.
About Cosmos Health Inc.
Cosmos Health Inc. is a diversified global healthcare company specializing in the development, manufacturing, and distribution of pharmaceutical and nutraceutical products. Its core segments include generic medicines, innovative drugs, nutraceuticals, biocides, medical devices, and telehealth services. The company leverages proprietary brands, research & development, and strategic partnerships to serve markets across Europe and beyond, emphasizing innovation, cost-efficiency, and a vertically integrated business model.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov